Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of GLPG3970 in Healthy Volunteers and Psoriasis Patients
NCT04106297Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of GLPG3970 in psoriasis (8 arms), sponsored by Galapagos NV. Primary endpoint: Treatment emergent adverse events. Started Sep 2019; status: completed.
02
Drugs
GLPG3970
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04106297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106297.